Artiva Biotherapeutics, Inc. (RTVA)
|Net Income (ttm)||-17.99M|
Artiva Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
South Korea's pharmaceutical and biopharma companies are ramping up efforts to get listed on the Nasdaq market, hoping to follow in the footsteps of Korean e-commerce giant Coupang with their US market ...
Artiva Biotherapeutics' mission is to deliver highly effective, off-the-shelf, allogeneic, natural killer (NK) cell-based therapies that are safe and accessible to cancer patients. Our established manufacturing-first approach has enabled us to produce, store and ship our product candidates and make them accessible like traditional protein biologic therapies. Our lead product candidate, AB-101, is an off-the-shelf NK cell therapy that is currently being studied in a Phase 1/2 trial with rituximab in patients with non-Hodgkin’s lymphoma (NHL). ... [Read more...]
|IPO Date |
Fred Aslan, M.D.
|Stock Exchange |
|Ticker Symbol |